🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “Karyopharm Therapeutics Inc” Clear

  1. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics Inc

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  2. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  3. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  4. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  5. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  6. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  7. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  8. A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

    phase 2 other active

    1 trial

  9. Abemaciclib, dexamethasone, ixazomib, pomalidomide

    Karyopharm Therapeutics Inc

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  10. Cyclophosphamide

    Karyopharm Therapeutics Inc

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  11. Decitabine

    Karyopharm Therapeutics Inc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  12. Docetaxel

    Karyopharm Therapeutics Inc

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  13. Elotuzumab, Selinexor, and Dexamethasone (ESd)

    Karyopharm Therapeutics Inc

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  14. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  15. KPT-8602

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule completed

    1 trial

  16. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm Therapeutics Inc

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  17. Open Label Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule terminated

    1 trial

  18. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm Therapeutics Inc

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  19. Pacritinib

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  20. Pembrolizumab

    Karyopharm Therapeutics Inc

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  21. SELINEXOR

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  22. Selinexor

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    2 trials

  23. Selinexor

    Karyopharm Therapeutics Inc

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

  24. Selinexor

    Karyopharm Therapeutics Inc

    Thymoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources